Research & Development News Channel

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators. The findings are published in the Journal of Translational Medicine.

Treatments in weeks, not months: Scientists develop ambitious pandemic response plan

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed new and better treatments that the newly diagnosed and recently exposed could take at home to prevent serious illness.

Scientists identify antibodies that can neutralize omicron

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

By identifying the targets of these "broadly neutralizing" antibodies on the spike protein, it might be possible to design vaccines and antibody treatments that will be effective against not only the omicron variant but other variants that may emerge in the future,

Stopping dementia at the nose with combination of rifampicin and resveratrol

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, had previously shown in a study using mice that the antibiotic rifampicin removes oligomers from the brain and improves cognitive function. However, the drug has been associated with side effects such as liver damage.

New study adds more evidence for Omicron immune evasion

A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune protection conferred by vaccines and natural infection and suggests the need for new vaccines and treatments that anticipate how the virus may soon evolve.

COVID-19 vaccine protection wanes after three months, study suggests

The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses, a study says.

The findings - drawn from datasets in two countries - suggest that booster programmes are needed to help maintain protection from severe disease in those vaccinated with Oxford-Astra Zeneca, experts say.

New study associates mask laws to reduction of COVID-19 deaths

A study of the impact of national face mask laws on COVID-19 mortality in 44 countries with a combined population of nearly one billion people found that, over time, the increase in COVID-19 related deaths was significantly slower in countries that imposed mask laws compared to countries that did not.

Research & Development News

COVID-19 can trigger self-attacking antibodies

Treatments in weeks, not months: Scientists develop ambitious pandemic response plan

Scientists identify antibodies that can neutralize omicron

Stopping dementia at the nose with combination of rifampicin and resveratrol

New study adds more evidence for Omicron immune evasion

COVID-19 vaccine protection wanes after three months, study suggests

New study associates mask laws to reduction of COVID-19 deaths

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs